| Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma |
NCT03092375: Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects |
|
|
| Completed | 3b | 177 | US | Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Glecaprevir/Pibrentasvir, GLE/PIB (Glecaprevir/Pibrentasvir), Ribavirin 200Mg Tablet, Ribasphere 200Mg Tablet | University of Florida, University of North Carolina, Chapel Hill, AbbVie | Hepatitis C, HCV | 12/18 | 02/20 | | |
| Completed | 3 | 304 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET, Placebo for ABT-493/ABT-530 | AbbVie | Chronic Hepatitis C Virus (HCV) Infection | 09/16 | 02/17 | | |
| Completed | 3 | 121 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Hepatitis C Virus | 10/16 | 01/17 | | |
| Completed | 3 | 104 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Chronic Hepatitis C Virus (HCV) Infection | 10/16 | 01/17 | | |
| Completed | 3 | 506 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET, Sofosbuvir, Sovaldi, Daclatasvir, Daklinza | AbbVie | Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus | 10/16 | 02/17 | | |
| Completed | 3 | 146 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Hepatitis C Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis | 10/16 | 02/17 | | |
CERTAIN-1, NCT02707952: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection |
|
|
| Completed | 3 | 295 | NA | ABT-493/ABT-530, Glecaprevir/Pibrentasvir, glecaprevir (ABT-493), pibrentasvir (ABT-530), OBV/PTV/r, Ombitasvir/paritaprevir/ritonavir, ombitasvir (ABT-267), paritaprevir (ABT-450), norvir (ritonavir) | AbbVie | Chronic Hepatitis C Virus, Hepatitis C Virus | 11/16 | 02/17 | | |
| Completed | 3 | 703 | NA | ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Chronic Hepatitis C, Hepatitis C Virus, HCV | 01/17 | 01/17 | | |
CERTAIN-2, NCT02723084: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection |
|
|
| Completed | 3 | 136 | NA | ABT-493/ABT-530, glecaprevir/pibrentasvir, glecaprevir (ABT-493), pibrentasvir (ABT-530), sofosbuvir (SOF), ribavirin (RBV) | AbbVie | Chronic Hepatitis C Virus, Hepatitis C Virus | 01/17 | 03/17 | | |
EXPEDITION-2, NCT02738138 / 2015-005577-20: A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection |
|
|
| Completed | 3 | 153 | NA | ABT-493 coformulated with ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics | 03/17 | 06/17 | | |
| Completed | 3 | 100 | NA | glecaprevir/pibrentasvir, glecaprevir also known as ABT-493, pibrentasvir also known as ABT-530, MAVYRET | AbbVie | Chronic Hepatitis C, HCV, Hepatitis C Virus | 04/17 | 06/17 | | |
| Completed | 3 | 101 | Canada, US, Europe, RoW | Glecaprevir/pibrentasvir, ABT-493/ABT-530, MAVYRET | AbbVie | Hepatitis C Virus (HCV) | 02/18 | 06/18 | | |
| Completed | 3 | 84 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir, ABT-493/ABT-530, MAVYRET™ | AbbVie | Hepatitis C Virus (HCV) | 06/18 | 08/18 | | |
NCT03212521 / 2016-004876-23: Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 |
|
|
| Completed | 3 | 230 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir, ABT-493/ABT-530, MAVYRET™ | AbbVie | Hepatitis C Virus (HCV) | 08/18 | 08/18 | | |
VOYAGE-1, NCT03222583: A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection |
|
|
| Completed | 3 | 546 | RoW | Placebo, Glecaprevir/Pibrentasvir, ABT-493/ABT-530, MAVYRET™ | AbbVie | Hepatitis C Virus (HCV) | 10/18 | 02/19 | | |
VOYAGE-2, NCT03235349: Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection |
|
|
| Completed | 3 | 160 | RoW | Glecaprevir/Pibrentasvir, ABT-493/ABT-530, MAVYRET™ | AbbVie | Hepatitis C Virus (HCV) | 11/18 | 02/19 | | |
2017-000694-37: A study to evaluate how effective and safe a simplified treatment monitoring strategy is when applied to people with chronic hepatitis C virus infection without liver disease and taking glecaprevir/pibrentasvir for 8 weeks |
|
|
| Completed | 3 | 375 | Europe | glecaprevir/pibrentasvir, ABT-493/ABT-530, Film-coated tablet | University of New South Wales Sydney, Abbvie Pty Ltd, University of New South Wales Sydney | Chronic hepatitis C virus infection, Chronic hepatitis C infection is infection with hepatitis C virus for more than 6 months, Diseases [C] - Virus Diseases [C02] | | | | |
SMART-C, NCT03117569: Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients |
|
|
| Completed | 3 | 380 | Europe, Canada, US, RoW | glecaprevir (300mg)/pibrentasvir (120mg), Mavyret | Kirby Institute | Hepatitis C, Chronic | 12/18 | 12/18 | | |
NCT03219216: A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection |
|
|
| Completed | 3 | 100 | RoW | Glecaprevir/Pibrentasvir, ABT-493, ABT-530, MAVYRET | AbbVie | Hepatitis C Virus (HCV) | 03/19 | 03/19 | | |
| Completed | 3 | 343 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir, ABT-493, ABT-530 | AbbVie | Hepatitis C Virus (HCV) | 07/19 | 11/19 | | |
NCT04017338: Transplantation Using Hepatitis C Positive Donors, A Safety Trial |
|
|
| Recruiting | 3 | 40 | Canada | Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Maviret, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion, Normothermic EVLP | Jordan Feld, University Health Network, Toronto | Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection, Kidney Pancreas Infection, Hepatitis C | 12/20 | 12/24 | | |
| Completed | 3 | 83 | Europe, RoW | Paritaprevir/ritonavir/ombitasvir, Viekira Pak, Dasabuvir, Ribavirin, Glecaprevir/pibrentasvir | Kirby Institute, AbbVie | Hepatitis C, Acute | 04/21 | 04/21 | | |
MAGELLAN-3, NCT02939989 / 2016-002491-26: Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study |
|
|
| Completed | 3 | 33 | Europe, Canada, US, RoW | Sofosbuvir, SOVALDI, Glecaprevir/Pibrentasvir, ABT-493/ABT-530, MAVYRET, MAVIRET, Ribavirin | AbbVie | Hepatitis C Virus Infection | 05/21 | 07/21 | | |
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Completed | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 09/24 | 09/24 | | |
NCT02243293 / 2014-002927-90: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection |
|
|
| Completed | 2/3 | 694 | NA | ABT-493, glecaprevir, ABT-530, pibrentasvir, ribavirin (RBV), ABT-493/ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, MAVYRET | AbbVie | Chronic Hepatitis C, Hepatitis C Virus | 10/16 | 02/17 | | |
NCT02446717 / 2015-002350-13: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy |
|
|
| Completed | 2/3 | 141 | NA | ABT-493, ABT-530, ABT-493 also known as glecaprevir, ABT-530 also known as pibrentasvir, ABT-493/ABT-530 (ABT-493 coformulated with ABT-267) also known as MAVYRET, ribavirin (RBV), ABT-493/ABT-530, MAVYRET | AbbVie | Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced | 12/16 | 01/17 | | |
DORA, NCT03067129 / 2016-004102-34: A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 2/3 | 129 | Europe, Canada, Japan, US, RoW | Glecaprevir/Pibrentasvir Adult Formulation, ABT-493/ABT-530, MAVYRET®, Glecaprevir + Pibrentasvir Pediatric Formulation | AbbVie | Hepatitis C Virus (HCV) | 05/20 | 09/22 | | |
| Completed | 2/3 | 54 | US | Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Epclusa, Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET], Mavyret | Ohio State University | Kidney Transplant, Hepatitis C, HCV | 04/21 | 04/21 | | |
NCT05446857: Glecaprevir/Pibrentasvir for the Treatment of PTSD |
|
|
| Completed | 2/3 | 10 | US | Glecaprevir / Pibrentasvir Pill, Mavyret | White River Junction Veterans Affairs Medical Center | PTSD | 04/24 | 04/24 | | |
NCT05637879: Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder |
|
|
| Recruiting | 2/3 | 92 | US | Glecaprevir/pibrentasvir, Mavyret, Placebo | White River Junction Veterans Affairs Medical Center | PTSD | 12/25 | 09/26 | | |
